Steven R Messé1, Gary S Gronseth1, David M Kent1, Jorge R Kizer1, Shunichi Homma1, Lee Rosterman1, John D Carroll1, Koto Ishida1, Navdeep Sangha1, Scott E Kasner1. 1. From the Department of Neurology (S.R.M., S.E.K.), University of Pennsylvania School of Medicine, Philadelphia; Department of Neurology (G.S.G., L.R.), University of Kansas Medical Center, MO; Institute for Clinical Research and Health Policy Studies (D.M.K.), Tufts University School of Medicine, Boston, MA; Cardiology Section (J.R.K.), San Francisco Veterans Affairs Health Care System, and Departments of Medicine, and Epidemiology and Biostatistics (J.R.K.), University of California San Francisco; Division of Cardiology (S.H.), Columbia University Medical Center, New York; Department of Medicine (Cardiology) (J.D.C.), University of Colorado School of Medicine, Aurora; Department of Neurology (K.I.), New York University; and Department of Neurology (N.S.), Kaiser Permanente, Los Angeles, CA.
Abstract
OBJECTIVE: To update the 2016 American Academy of Neurology (AAN) practice advisory for patients with stroke and patent foramen ovale (PFO). METHODS: The guideline panel followed the AAN 2017 guideline development process to systematically review studies published through December 2017 and formulate recommendations. MAJOR RECOMMENDATIONS: In patients being considered for PFO closure, clinicians should ensure that an appropriately thorough evaluation has been performed to rule out alternative mechanisms of stroke (level B). In patients with a higher risk alternative mechanism of stroke identified, clinicians should not routinely recommend PFO closure (level B). Clinicians should counsel patients that having a PFO is common; that it occurs in about 1 in 4 adults in the general population; that it is difficult to determine with certainty whether their PFO caused their stroke; and that PFO closure probably reduces recurrent stroke risk in select patients (level B). In patients younger than 60 years with a PFO and embolic-appearing infarct and no other mechanism of stroke identified, clinicians may recommend closure following a discussion of potential benefits (absolute recurrent stroke risk reduction of 3.4% at 5 years) and risks (periprocedural complication rate of 3.9% and increased absolute rate of non-periprocedural atrial fibrillation of 0.33% per year) (level C). In patients who opt to receive medical therapy alone without PFO closure, clinicians may recommend an antiplatelet medication such as aspirin or anticoagulation (level C).
OBJECTIVE: To update the 2016 American Academy of Neurology (AAN) practice advisory for patients with stroke and patent foramen ovale (PFO). METHODS: The guideline panel followed the AAN 2017 guideline development process to systematically review studies published through December 2017 and formulate recommendations. MAJOR RECOMMENDATIONS: In patients being considered for PFO closure, clinicians should ensure that an appropriately thorough evaluation has been performed to rule out alternative mechanisms of stroke (level B). In patients with a higher risk alternative mechanism of stroke identified, clinicians should not routinely recommend PFO closure (level B). Clinicians should counsel patients that having a PFO is common; that it occurs in about 1 in 4 adults in the general population; that it is difficult to determine with certainty whether their PFO caused their stroke; and that PFO closure probably reduces recurrent stroke risk in select patients (level B). In patients younger than 60 years with a PFO and embolic-appearing infarct and no other mechanism of stroke identified, clinicians may recommend closure following a discussion of potential benefits (absolute recurrent stroke risk reduction of 3.4% at 5 years) and risks (periprocedural complication rate of 3.9% and increased absolute rate of non-periprocedural atrial fibrillation of 0.33% per year) (level C). In patients who opt to receive medical therapy alone without PFO closure, clinicians may recommend an antiplatelet medication such as aspirin or anticoagulation (level C).
Authors: Aristeidis H Katsanos; Theodora Psaltopoulou; Theodoros N Sergentanis; Alexandra Frogoudaki; Agathi-Rosa Vrettou; Ignatios Ikonomidis; Ioannis Paraskevaidis; John Parissis; Chrysa Bogiatzi; Christina Zompola; John Ellul; Nikolaos Triantafyllou; Konstantinos Voumvourakis; Athanassios P Kyritsis; Sotirios Giannopoulos; Anne W Alexandrov; Andrei V Alexandrov; Georgios Tsivgoulis Journal: Ann Neurol Date: 2016-03-11 Impact factor: 10.422
Authors: Michael Handke; Andreas Harloff; Manfred Olschewski; Andreas Hetzel; Annette Geibel Journal: N Engl J Med Date: 2007-11-29 Impact factor: 91.245
Authors: Hans-Christoph Diener; Ralph L Sacco; J Donald Easton; Christopher B Granger; Richard A Bernstein; Shinichiro Uchiyama; Jörg Kreuzer; Lisa Cronin; Daniel Cotton; Claudia Grauer; Martina Brueckmann; Marina Chernyatina; Geoffrey Donnan; José M Ferro; Martin Grond; Bernd Kallmünzer; Jerzy Krupinski; Byung-Chul Lee; Robin Lemmens; Jaime Masjuan; Miroslav Odinak; Jeffrey L Saver; Peter D Schellinger; Danilo Toni; Kazunori Toyoda Journal: N Engl J Med Date: 2019-05-16 Impact factor: 91.245
Authors: Lars Søndergaard; Scott E Kasner; John F Rhodes; Grethe Andersen; Helle K Iversen; Jens E Nielsen-Kudsk; Magnus Settergren; Christina Sjöstrand; Risto O Roine; David Hildick-Smith; J David Spence; Lars Thomassen Journal: N Engl J Med Date: 2017-09-14 Impact factor: 91.245
Authors: Roel J R Snijder; Justin G L M Luermans; Albert H de Heij; Vincent Thijs; Wouter J Schonewille; Alexander Van De Bruaene; Martin J Swaans; Werner I H L Budts; Martijn C Post Journal: J Am Heart Assoc Date: 2016-12-01 Impact factor: 5.501
Authors: Alexander T Cohen; Robert A Harrington; Samuel Z Goldhaber; Russell D Hull; Brian L Wiens; Alex Gold; Adrian F Hernandez; C Michael Gibson Journal: N Engl J Med Date: 2016-05-27 Impact factor: 91.245
Authors: Peter B Sporns; Heather J Fullerton; Sarah Lee; Helen Kim; Warren D Lo; Mark T Mackay; Moritz Wildgruber Journal: Nat Rev Dis Primers Date: 2022-02-24 Impact factor: 52.329
Authors: Nikita Chhabra; Benzion Blech; David Fortuin; Susan Wilansky; Bart M Demaerschalk; Oana M Dumitrascu Journal: Neurohospitalist Date: 2022-02-20
Authors: Davor Vukadinović; Bruno Scheller; Christian Ukena; Sebastian Ewen; Felix Mahfoud; Michael Böhm Journal: Clin Res Cardiol Date: 2021-11-10 Impact factor: 5.460
Authors: Paola Nicolini; Andrea Arighi; Elisa Gherbesi; Francesco Maria Lo Russo; Clara Mandelli; Giuseppina Schinco; Stefano Carugo; Tiziano Lucchi Journal: Brain Sci Date: 2022-06-13